

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: NetraMark Holdings Inc (formerly "Nurosene Health Inc.") (the "Issuer" or the "Company").

Trading Symbol: AIAI

Number of Outstanding Listed Securities: 66,827,195

Date: March 05, 2024

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

NetraMark announced the launch of its NetraAI Lab offering, which is designed to make it easier and more affordable than ever for biopharmaceutical companies to experience the benefits of how its NetraAI solution can improve clinical trials success rates.

The Company also announced the presentation of new data demonstrating that the application of its NetraAI clinical solution to data sets of fewer than 400 patients can identify variables that predict efficacy and placebo responses in psychiatric clinical trials with high statistical significance, providing a novel approach to de-risk clinical trials for psychiatric therapies. The data was presented on February 22, 2024 at the ISCTM 20th Annual Meeting in Washington, DC.

2. Provide a general overview and discussion of the activities of management.

Management has worked to present new data supporting the potential of its proprietary NetraAI clinical trial solution to de-risk clinical trials for neurology therapies; and to generate novel insights into key drivers of Parkinson's Disease.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

NetraMark launched its NetraAI Lab offering, which is designed to make it easier and more affordable than ever for biopharmaceutical companies to experience the benefits of how its NetraAI solution can improve clinical trials success rates. Customers participating in the offering will receive these valuable deliverables in only four weeks.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

NetraMark has signed a fourth contract in a new indication with a large, publicly listed biopharmaceutical company, pursuant to a previously announced Master Service Agreement. The Companies are unrelated.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable.

8. Describe the acquisition of new customers or loss of customers.

Not Applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not Applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not Applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not Applicable.

14. Provide details of any securities issued and options or warrants granted.

272,747 Common Shares were issued pursuant to Compensation for Services at a deemed price of CAD \$0.305 per share.

15. Provide details of any loans to or by Related Persons.

Not Applicable.

16. Provide details of any changes in directors, officers or committee members.

Not Applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis (the "MD&A") under the headings "Risk Factors" including:

NetraMark has a history of operating losses and is still in the early stages of development. We have generated minimal revenue and have incurred, and continue to incur, significant expenses. Accordingly, we expect to continue to incur operating losses over the next several years. Our operating expenses and net losses going forward may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our operating expenses will increase in the foreseeable future as we continue to invest in and develop our NetraMark suite of products (the "NetraMark Products"); NetraAI, NetraPlacebo, NetraGPT, build the sales and marketing programs, hire additional data scientists, bioinformaticians, software engineers and other personnel.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 05, 2024.

George Achilleos
Name of Director or Senior
Officer

(s) George Achilleos
Signature
Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer NetraMark Holdings Inc.	For Month End February 29 2024	Date of Report 2024/03/05
Issuer Address 1655 Dupont St – Suite 101		
City/Province/Postal Code Toronto, ON M6P 3T1	Issuer Fax No.	Issuer Telephone No. (403) 681-2549
Contact Name George Achilleos	Contact Position CEO	Contact Telephone No. 403 701 1756
Contact Email Address george@netramark.com	Web Site Address https://www.netramark.com/	